Infinity Pharmaceuticals, Inc.
INFI
INFI was delisted on the 13th of September, 2023.
63 hedge funds and large institutions have $58.1M invested in Infinity Pharmaceuticals, Inc. in 2019 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 14 increasing their positions, 17 reducing their positions, and 10 closing their positions.
1,771% more call options, than puts
Call options by funds: $131K | Put options by funds: $7K
60% more capital invested
Capital invested by funds: $36.3M → $58.1M (+$21.8M)
2% less funds holding
Funds holding: 64 → 63 (-1)
10% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 10
18% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$264K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$239K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$118K |
| 4 |
Renaissance Technologies
New York
|
+$101K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$91.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$346K |
| 2 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$134K |
| 3 |
Two Sigma Investments
New York
|
-$71.3K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$51.4K |
| 5 |
AIM
Alambic Investment Management
Belvedere,
California
|
-$46K |
INFI Hedge Fund Activity: Q1 2019 in Review
63 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Infinity Pharmaceuticals, Inc. (INFI) for Q1 2019, worth a combined $58.1M — up 60% from $36.3M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of INFI and 9 opened new positions — a net loss of 1 holder — while 17 trimmed existing stakes and 14 added.
The largest buyer was Vanguard Group, adding an estimated $264K. The largest seller was Anson Funds Management, exiting entirely with an estimated $346K sold.
- 63 institutional investors held Infinity Pharmaceuticals, Inc. (INFI) as of Q1 2019, down from 64 in Q4 2018.
- Funds reported $58.1M of Infinity Pharmaceuticals, Inc. stock for Q1 2019, up 60% quarter-over-quarter.
- 9 funds opened new Infinity Pharmaceuticals, Inc. positions in Q1 2019 and 10 closed out, a net change of -1 holder.
- The largest Infinity Pharmaceuticals, Inc. buyer in Q1 2019 was Vanguard Group, an estimated $264K added.
- The largest Infinity Pharmaceuticals, Inc. seller in Q1 2019 was Anson Funds Management, an estimated $346K sold.
Based on aggregated 13F filings for Q1 2019.